The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis

OBJECTIVE: The aim of this study was to evaluate the budget impact of introducing tildrakizumab for moderate-to-severe plaque psoriasis from a US health plan perspective. METHODS: A budget impact model estimated costs before and after the adoption of tildrakizumab to a hypothetical US health plan wi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacoecon Open
Hlavní autoři: Carrico, Justin, Zhao, Yang, Jia, Xiaoying, Brodtkorb, Thor-Henrik, Mendelsohn, Alan, Lowry, Simon
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2020
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7688845/
https://ncbi.nlm.nih.gov/pubmed/32219733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-020-00208-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky